Who is sponsoring NCT00519142?

NCT00519142 is sponsored by Elixir Pharmaceuticals.

What condition does NCT00519142 study?

NCT00519142 studies Diabetes Mellitus, Type 2.

What drugs are being tested in NCT00519142?

Interventions: placebo for mitiglinide, mitiglinide, mitiglinide.

What is the status of NCT00519142?

NCT00519142 is currently COMPLETED.

Last reviewed 2009-09-16 · How we verify

A Rapid Onset and Short Duration Insulin Secretogogue, Mitiglinide, in Combination With Metformin Versus Metformin Alone in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial for 6 Months

NCT00519142 Phase 3 COMPLETED

The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which measures improvement in blood sugar after of treatment.

Details

Lead sponsor	Elixir Pharmaceuticals
Phase	Phase 3
Status	COMPLETED
Enrolment	367
Start date	2007-08
Completion	2008-10

Conditions

Diabetes Mellitus, Type 2

Interventions

placebo for mitiglinide
mitiglinide
mitiglinide

Primary outcomes

change from baseline in HbA1c — after 24 weeks of treatment

Countries

United States, Puerto Rico